Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Frontiers in Nanomaterials for Clinical Imaging and Selective Therapy"
Deadline for manuscript submissions: 31 December 2019.
Interests: Pablo Botella coordinates the Nanomedicine Group at the Instituto de Tecnología Química, addressing medical nanoscale-structured material and devices for targeted delivery and controlled release of drugs and other biologically active agents. Special interest is dedicated to the development of organic-inorganic nanohybrid-based stimuli-responsive systems, as well as stable radioactive nanoparticles for enhancing diagnostic imaging. Also important in his research is the study of the immune reaction and protein corona formation after nanoparticle systemic administration, as well as its application to new cancer biomarker detection
Interests: Christopher Landry is Chair of the Department of Chemistry at the University of Vermont. Over the past 22 years as an independent faculty member, he has studied the applications of porous nanoparticles in catalysis and biomedicine. He has prepared novel transition metal oxides for photocatalysis of organic compounds, and his research group has developed nanoparticle-based systems using tethered enzymes for simultaneous sensing and decontamination of organophosphorus toxins. In addition to designing in vivo drug delivery systems, including materials for simultaneous diagnosis and treatment of disease, his interests in biomedicine include fundamental studies on the adsorption and exchange of proteins at nanoparticle surfaces in biological media
It is more than two decades since the first nanomedicines were released on the market. During this time, a wide range of materials and compositions have been tested, mostly at the preclinical stage. The focus of these studies has been to address key clinical goals, such as the early diagnosis of degenerative diseases and the selective treatment of target cells or tissues. Currently, a new generation of imaging agents and nanomaterial-based pharmaceuticals are being developed, with improved biocompatibility, pharmacokinetics, and diagnostic and therapeutic efficacies. Once bioavailability limitations and regulatory matters concerning their somewhat complex compositions are addressed, rapid commercialization of these products is expected.
In this context, this Special Issue focuses on the development of novel nanoplatforms with applications in bioimaging (e.g., MRI, PET, HIFU), and/or suitable to promote selective therapies (then, minimizing side effects) through targeted delivery and specific intracellular drug release mechanisms. Manuscripts at both the preclinical and clinical levels are encouraged.
Prof. Pablo Botella
Prof. Christopher C. Landry
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nanomaterials is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- selective therapy
- targeted delivery
- intracellular release